Rosiglitazone and Metformin Have Opposite Effects on Intestinal Absorption of Oligopeptides via the Proton-Dependent PepT1 Transporter

Abstract

The intestinal H(ϩ)/peptide cotransporter 1 (PepT1) plays a major role in nitrogen supply to the body by mediating intestinal absorption of di-and tripeptides. Previous studies have reported that in animal models of type 2 diabetes/obesity, PepT1 activity and expression were markedly reduced. This prompted us to investigate the effects of two antidiabetic drugs, rosiglitazone and metformin, on PepT1 activity/expression in a murine diet-induced obesity model. C57BL/6J male mice were fed a high-fat diet (HFD) or a standard chow for 6 weeks and then were treated for 7 days with metformin (250 mg/kg/day) and/or rosiglitazone (8 mg/kg/day). For in vitro studies, Caco-2 enterocyte-like cells were treated for 7 days with metformin (10 mM) and/or rosiglitazone (10 M). A 7-day rosiglitazone treatment increased PepT1 activity and prevented the 2-fold HFD-induced reduction in PepT1 transport. Metformin alone did not modify PepT1 activity but counteracted rosiglitazone-induced PepT1-mediated transport. As with the in vivo studies, rosiglitazone treatment up-regulated PepT1 transport activity with concomitant induction of S6 ribosomal protein activation in vitro. Furthermore, metformin decreased PepT1 expression (mRNA and protein) and its transport activity. The effect of metformin was linked to a reduction of phosphorylated S6 ribosomal protein (active form) and of phosphorylated 4E-BP1 (inactive form), a translation repressor. These data demonstrate that two antidiabetic drugs exert opposite effects on the PepT1 transport function probably through direct action on enterocytes. In our type 2 diabetes/obesity model, rosiglitazone, a peroxisome proliferator-activated receptor-␥ agonist compensated for the HFD-induced PepT1 down-regulation, whereas metformin reversed rosiglitazone activity at the translational level.

High fat diet modulates the protein content of nutrient transporters in the small intestine of mice: possible involvement of PKA and PKC activity

“…With regards to PEPT1, a previous study reported that mice fed an HFD exhibited reduced [ 3 H] Gly-Sar transport, reflecting low PEPT1 activity [32]. Indeed, it is plausible that this observed decrease in activity could be the consequence of the diminished PEPT1 content observed in the mice fed an HFD.…”

The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism

“…This dose of oral rosiglitazone (estimated at 8 mg/kg/day) was previously shown by our laboratory to significantly suppress chemical carcinogenesis in mice [41] and to block ultraviolet B-induced immune suppression [1]. Similarly, this dose is within the range of doses that have pharmacologic activity in mice [44,45]. C57BL/6J or NOD SCID mice were then injected intradermally with either 1 × 10 6 or 5 × 10 6 PDV tumor cells.…”

Epidermal PPARγ influences subcutaneous tumor growth and acts through TNF-α to regulate contact hypersensitivity and the acute photoresponse

“…The estimated daily intake was 8 mg/kg/day. Oral rosiglitazone has been shown to be systemically active in mice at doses of 3-8 mg/kg/day [ 58 , 59 ]. An approximately 2.5 × 2.5-cm area of the distal back skin of these mice were treated with 7500 J/m 2 UVB or were left untreated.…”